Clinical Trials Browser

Neoplasm, Residual × Genitourinary × 90 days × Clear all

NCT07112612 2026-01-12

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting

Prostatic Neoplasms, Neoplasm, Residual